Evidence map›Paper›PMID 29944651›Full record

Trial reportPLoS medicine2018

Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial.

Matthew E Coldiron, Bachir Assao, Anne-Laure Page, Matt D T Hitchings, Gabriel Alcoba, Iza Ciglenecki, Céline Langendorf, Christopher Mambula, Eric Adehossi, Fati Sidikou and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PLoS medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02724046 (Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02724046 phase4completednot on this map

Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response

TypeinterventionalSponsorEpicentreRan2017 to 2017Enrolled300ConditionsMeningitis, MeningococcalArmsCiprofloxacin
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Recent Evolution of Susceptibility to Beta-Lactams inAntibiotics (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Molecular detection of fluoroquinolone-resistantFrontiers in cellular and infection microbiology · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Matthew E ColdironEpicentre, Paris, France.ORCID 0000-0002-3345-5971
Bachir AssaoEpicentre, Maradi, Niger.
Anne-Laure PageEpicentre, Paris, France.ORCID 0000-0001-7952-3178
Matt D T HitchingsHarvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID 0000-0003-2327-3557
Gabriel AlcobaMédecins Sans Frontières, Geneva, Switzerland.
Iza CigleneckiMédecins Sans Frontières, Geneva, Switzerland.
Céline LangendorfEpicentre, Paris, France.
Christopher MambulaMédecins Sans Frontières, Paris, France.
Eric AdehossiNiamey National Hospital, Niamey, Niger.
Fati SidikouCentre de Recherche Médicale et Sanitaire, Niamey, Niger.
Elhadji Ibrahim TassiouMinistry of Public Health, Madarounfa, Niger.
Victoire De LastoursDepartment of Internal Medicine, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Paris, France.
Rebecca F GraisEpicentre, Paris, France.ORCID 0000-0002-5037-8218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntibiotic prophylaxis for contacts of meningitis cases is not recommended during outbreaks in the African meningitis belt. We assessed the effectiveness of single-dose oral ciprofloxacin administered to household contacts and in village-wide distributions on the overall attack rate (AR) in an outbreak of meningococcal meningitis. METHODS AND

findingsIn this 3-arm, open-label, cluster-randomized trial during a meningococcal meningitis outbreak in Madarounfa District, Niger, villages notifying a suspected case were randomly assigned (1:1:1) to standard care (the control arm), single-dose oral ciprofloxacin for household contacts within 24 hours of case notification, or village-wide distribution of ciprofloxacin within 72 hours of first case notification. The primary outcome was the overall AR of suspected meningitis after inclusion. A random sample of 20 participating villages was enrolled to document any changes in fecal carriage prevalence of ciprofloxacin-resistant and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae before and after the intervention. Between April 22 and May 18, 2017, 49 villages were included: 17 to the control arm, 17 to household prophylaxis, and 15 to village-wide prophylaxis. A total of 248 cases were notified in the study after the index cases. The AR was 451 per 100,000 persons in the control arm, 386 per 100,000 persons in the household prophylaxis arm (t test versus control p = 0.68), and 190 per 100,000 persons in the village-wide prophylaxis arm (t test versus control p = 0.032). The adjusted AR ratio between the household prophylaxis arm and the control arm was 0.94 (95% CI 0.52-1.73, p = 0.85), and the adjusted AR ratio between the village-wide prophylaxis arm and the control arm was 0.40 (95% CI 0.19‒0.87, p = 0.022). No adverse events were notified. Baseline carriage prevalence of ciprofloxacin-resistant Enterobacteriaceae was 95% and of ESBL-producing Enterobacteriaceae was >90%, and did not change post-intervention. One limitation of the study was the small number of cerebrospinal fluid samples sent for confirmatory testing.

conclusionsVillage-wide distribution of single-dose oral ciprofloxacin within 72 hours of case notification reduced overall meningitis AR. Distributions of ciprofloxacin could be an effective tool in future meningitis outbreak responses, but further studies investigating length of protection, effectiveness in urban settings, and potential impact on antimicrobial resistance patterns should be carried out.

trial registrationClinicalTrials.gov NCT02724046.

Indexed as

EpidemicsAdministration, OralAdolescentAdultAnti-Bacterial AgentsAntibiotic ProphylaxisChildChild, PreschoolCiprofloxacinFemaleHumansInfantMaleMeningitis, MeningococcalNeisseria meningitidisNigerAnti-Bacterial AgentsCiprofloxacin

Identifiers

PMID29944651
PMCPMC6019097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.